Literature DB >> 28532711

Psychiatric comorbidities in new onset epilepsy: Should they be always investigated?

Andres M Kanner1.   

Abstract

The new definition of epilepsy establishes that epilepsy is not only a disorder presenting with epileptic seizures but it can be often associated with cognitive and psychiatric comorbidities. In fact, the prevalence of psychiatric comorbidities is relatively high in patients with epilepsy (PWE), as one in three patients will have experienced a psychiatric disorder in the course of their life, with mood and anxiety disorders being the most frequent. Psychiatric comorbidities often precede the onset of the seizure disorder, and affect the life of these patients and the course of the seizure disorder at several levels, including a worse tolerance of pharmacotherapy with antiepileptic drugs (AEDs), in particular the development of iatrogenic psychiatric symptoms from pharmacologic and surgical treatments, an increased mortality risk, a worse quality of life and higher economic burdens of the patient, family and society as a hole. Accordingly, psychiatric comorbidities should be recognized at the time of the initial evaluation of every PWE and their treatment needs to be incorporated within the overall therapeutic plan. This question is addressed in this article.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Antiepileptic drugs; Attention deficit disorder; Generalized anxiety disorder; Major depressive disorder; Quality of life; Temporal lobe epilepsy

Mesh:

Substances:

Year:  2017        PMID: 28532711     DOI: 10.1016/j.seizure.2017.04.007

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  16 in total

1.  Cannabidiol attenuates generalized tonic-clonic and suppresses limbic seizures in the genetically epilepsy-prone rats (GEPR-3) strain.

Authors:  Willian Lazarini-Lopes; Carolina Campos-Rodriguez; Norberto Garcia-Cairasco; Prosper N'Gouemo; Patrick A Forcelli
Journal:  Pharmacol Rep       Date:  2022-10-04       Impact factor: 3.919

2.  Management of Psychiatric Disorders in Patients of Epilepsy.

Authors:  Jahnavi S Kedare; Sachin P Baliga
Journal:  Indian J Psychiatry       Date:  2022-03-23       Impact factor: 2.983

3.  Prevalence and determinants of anxiety in patients with epilepsy during COVID-19 pandemic.

Authors:  Mohammad Gamal Sehlo; Wafaa Samir Mohamed; Usama Mahmoud Youssef; Shrouk Esam Lotfi; Ghada Mohamed Salah El-Deen
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2022-06-23

4.  Mechanisms of Psychiatric Comorbidities in Epilepsy.

Authors:  Jamie Maguire
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 5.  Recent Advances in Neuroimaging of Epilepsy.

Authors:  Adam M Goodman; Jerzy P Szaflarski
Journal:  Neurotherapeutics       Date:  2021-05-03       Impact factor: 7.620

Review 6.  Antiepileptic Drug Therapy in Patients with Drug-Resistant Epilepsy.

Authors:  Kang Min Park; Sung Eun Kim; Byung In Lee
Journal:  J Epilepsy Res       Date:  2019-06-30

7.  Environmental Enrichment and Brain Neuroplasticity in the Kainate Rat Model of Temporal Lobe Epilepsy.

Authors:  Vasavi R Gorantla; Sneha E Thomas; Richard M Millis
Journal:  J Epilepsy Res       Date:  2019-06-30

8.  Network Dysfunction in Comorbid Psychiatric Illnesses and Epilepsy.

Authors:  Phillip L W Colmers; Jamie Maguire
Journal:  Epilepsy Curr       Date:  2020-07-06       Impact factor: 7.500

9.  Sociodemographic and Clinical Variables of Depression among Patients with Epilepsy in a Neuropsychiatric Hospital in Nigeria.

Authors:  Nasir Olamide Madandola; Shehu Sale; Adebayo Sunday Adebisi; Ayodele Obembe; Auwal S Salihu; Abdulfatai Tomori Bakare; Ishak Abioda Danjuma
Journal:  Depress Res Treat       Date:  2020-02-12

10.  Comorbid mental disorders and quality of life of people with epilepsy attending primary health care clinics in rural Ethiopia.

Authors:  Ruth Tsigebrhan; Abebaw Fekadu; Girmay Medhin; Charles R Newton; Martin J Prince; Charlotte Hanlon
Journal:  PLoS One       Date:  2021-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.